Press release: NTRC launches the first HTS Assay for Arginase-1 inhibitors at ENA2018 Copy
NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018. Arginase-1 (Arg-1) is an important drug target for cancer immunotherapy.
Read more
Get this presentation about uHTS Copy
SLAS (Society for Laboratory Automation and Screening) visited Europe and the Pivot Park Screening Centre in June this year. During...
Read more
New predictive drug response biomarkers for approved kinase inhibitors
Press release, Oss, November, 02, 2018 Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new...
Read more
Funding Event 2018
We believe in connecting the right people to the right knowledge. Therefore, we organize the Funding Event on November 15th....
Read more
Community Meeting
On September 27th, the community meeting took place. We discussed about several topics. Attached the presentation. If you have any questions...
Read more
Noviogel acts as a novel wounds dressing
Full-thickness dorsal skin wounds in mice were treated with Noviogel for 3 and 7 days.
Read more
Dutch Heart Foundation, UMC Groningen and Pivot Park Screening Centre collaborate on heart failure High number of SMEs benefit greatly from the European Lead Factory
Scientists from UMC Groningen and Pivot Park Screening Centre have started a study with the objective to prevent one of...
Read more
A cup of coffee with … Sander van Asbeck
“It is our mission to develop the next generation of (nano)medicines; low in side-effects and high in efficacy."
Read more
NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents
New compounds include Herceptin® (trastuzumab), the antibody drug conjugate Kadcyla®, the SUMOylation inhibitor ML-792, and the selective BTK inhibitor acalabrutinib.
Read more